Valuation: Biogen Inc.

Market Cap 29.99B 26.06B 24.33B 22.34B 42.12B 2,858B 42.85B 287B 112B 1,425B 113B 110B 4,701B P/E 2026 *
37.2x
P/E 2027 * 17.9x
Enterprise Value 35.07B 30.48B 28.45B 26.12B 49.25B 3,343B 50.11B 336B 131B 1,667B 132B 129B 5,498B EV / Sales 2026 *
3.36x
EV / Sales 2027 * 3.07x
Free-Float
85.97%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week-1.01%
Current month-0.78%
1 month+6.25%
3 months+12.21%
6 months+15.93%
Current year+17.40%
1 week 176.04
Extreme 176.04
189.72
1 month 165.54
Extreme 165.54
193
Current year 134.7
Extreme 134.7
193
1 year 109
Extreme 109
193
3 years 99
Extreme 99
255.4
5 years 99
Extreme 99
317.45
10 years 99
Extreme 99
351.7
Manager TitleAgeSince
Chief Executive Officer 66 14/11/2022
Director of Finance/CFO 60 01/03/2025
Chief Tech/Sci/R&D Officer - 28/10/2024
Director TitleAgeSince
Director/Board Member 69 23/03/2010
Director/Board Member 77 01/01/2010
Director/Board Member 72 19/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-1.01% - - 29.99B
-0.44%+13.80%+32.84%-1.58% 76.15B
-0.67%-10.00%+19.77%+174.96% 48.89B
-4.18%+42.30%+42.30%+42.30% 47.83B
+1.01%+8.83%-52.93%-53.63% 41.37B
-0.91%-0.37%+51.76%+82.26% 24.23B
+0.58%-0.88%+99.49%-49.85% 21.89B
-0.81%-4.39%-7.53%+165.02% 19.25B
-7.35%-4.68%+64.90%+111.65% 17.14B
-0.16%-4.95%+67.46%+149.10% 15.66B
Average -1.34%+0.45%+35.34%+68.91% 34.71B
Weighted average by Cap. -1.16%+2.19%+28.03%+53.02%

Financials

2026 *2027 *
Net sales 10.42B 9.06B 8.46B 7.76B 14.64B 993B 14.89B 99.72B 39.06B 495B 39.15B 38.28B 1,634B 10.62B 9.23B 8.62B 7.91B 14.92B 1,013B 15.18B 102B 39.81B 505B 39.91B 39.03B 1,666B
Net income 953M 828M 773M 710M 1.34B 90.84B 1.36B 9.12B 3.57B 45.3B 3.58B 3.5B 149B 1.9B 1.65B 1.54B 1.41B 2.67B 181B 2.71B 18.17B 7.12B 90.28B 7.13B 6.98B 298B
Net Debt 5.08B 4.42B 4.12B 3.78B 7.14B 484B 7.26B 48.61B 19.04B 242B 19.09B 18.66B 797B 2.57B 2.23B 2.08B 1.91B 3.6B 245B 3.67B 24.55B 9.62B 122B 9.64B 9.43B 402B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
03/08/26 176.04 -0.78% 0
31/07/26 €177.42 -0.39% 117
30/07/26 €178.12 -6.11% 154
29/07/26 €189.72 +6.66% 390
28/07/26 €177.88 -0.33% 0
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
202.95USD
Average target price
235.32USD
Spread / Average Target
+15.95%

Quarterly revenue - Rate of surprise